Do eosinophil-targeting biologics affect COVID-19
patients?
There is no evidence for an enhanced susceptibility of patients on
anti-IL-5/IL-5R treatment to develop viral infections. Observational
studies in COVID-19 patients reported elevated eosinophil counts with a
favorable outcome, whereas eosinopenia was observed in more severe
cases.22,57 Neither was there proof of causation nor
evidence for enhanced tissue presence in lungs of COVID-19
patients.58